Please login to the form below

Article: Market access in Brazil

All eyes on Spinraza

Director Rachel Howard asks, “What does Brazil’s unprecedented risk-sharing agreement in Spinal Muscular Atrophy (SMA) mean for the future of market access in Brazil?

In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde (SUS). This is the first agreement in Brazil to include a risk-sharing model, in which the government only pays for the drug if there is improvement in the patient's health.

In a country where it typically takes years for innovative pharmaceutical products to be reimbursed in the public sector, manufacturers wishing to obtain market access for their products in Brazil will be watching this example closely to see how it plays out.

Read more on this article here: https://bit.ly/2qZ5HW1

1st November 2019

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.
Research Partnership
News:
Senior Analytics Specialist joins Research Partnership
Research Partnership
Article:
All change – how untangling human behaviour can encourage better health
Research Partnership
Webinar:
Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy
Research Partnership
News:
Therapy Watch COVID-19 tracker
Research Partnership
Events:
Patient Centricity and Engagement Conference 2021
Research Partnership